Trade

with

Dyax Corp
(NASDAQ: DYAX)
AdChoices
10.00
-0.19
-1.86%
After Hours :
10.00
0.00
0.00%

Open

10.23

Previous Close

10.19

Volume (Avg)

680.15k (954.00k)

Day's Range

10.00-10.28

52Wk Range

6.05-11.01

Market Cap.

1.36B

Dividend Rate ( Yield )

-

Beta

1.21

Shares Outstanding

136.21M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 53.93M

    • Net Income

    • -27.78M

    • Market Cap.

    • 1.36B

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -26.34

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.21

    • Forward P/E

    • -59.88

    • Price/Sales

    • 19.42

    • Price/Book Value

    • 13.48

    • Price/Cash flow

    • -136.99

      • EBITDA

      • -16.12M

      • Return on Capital %

      • -12.12

      • Return on Equity %

      • -51.30

      • Return on Assets %

      • -12.12

      • Book Value/Share

      • 0.76

      • Shares Outstanding

      • 136.21M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Buy
        • 1 Year Price Target

        • 13.00

        • Credit Rating

        • -

        • Analysts

        • 1

        • EPS Estimate

        • -0.17

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 72.80

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • 4.42

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 95.06

            • 82.75

            • Pre-Tax Margin

            • -26.34

            • 39.38

            • Net Profit Margin

            • -26.34

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 97.50

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -102.40

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 0.80

              • 0.76

              • Current Ratio

              • 12.60

              • 2.92

              • Quick Ratio

              • 12.27

              • 2.35

              • Interest Coverage

              • -0.55

              • 38.02

              • Leverage Ratio

              • 2.03

              • 2.21

              • Book Value/Share

              • 0.76

              • 4.75

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -73.53

                • 277.78

                • P/E Ratio 5-Year High

                • -79.70

                • 634.30

                • P/E Ratio 5-Year Low

                • -7.96

                • 124.82

                • Price/Sales Ratio

                • 19.42

                • 9.35

                • Price/Book Value

                • 13.48

                • 8.50

                • Price/Cash Flow Ratio

                • -136.99

                • 50.25

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -51.30

                    (-)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • -12.12

                    (-46.20)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • -5.20

                    (-)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • -

                  • 117.08k

                  • Inventory Turnover

                  • 1.00

                  • 1.48

                  • Asset Turnover

                  • 0.46

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -17.20M
                  Operating Margin
                  -31.89
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -136.99
                  Ownership

                  Institutional Ownership

                  94.41%

                  Top 10 Institutions

                  52.63%

                  Mutual Fund Ownership

                  48.52%

                  Float

                  73.42%

                  5% / Insider Ownership

                  0.80%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Federated Kaufmann Fund

                  •  

                    12,850,000

                  • -7.62

                  • 9.45

                  • PrimeCap Odyssey Aggressive Growth Fund

                  •  

                    7,822,690

                  • -1.60

                  • 5.75

                  • Fidelity® Select Biotechnology Portfolio

                  •  

                    6,674,338

                  • 0.00

                  • 4.90

                  • Vanguard US Opportunities

                  •  

                    3,307,140

                  • -8.02

                  • 2.43

                  • iShares Russell 2000 (AU)

                  •  

                    2,111,506

                  • -1.02

                  • 1.56

                  • Vanguard Total Stock Mkt Idx

                  •  

                    2,093,308

                  • 0.00

                  • 1.54

                  • Fidelity® Advisor Small Cap Opps Fund

                  •  

                    1,907,615

                  • 0.00

                  • 1.40

                  • iShares Nasdaq Biotechnology

                  •  

                    1,808,199

                  • -0.69

                  • 1.34

                  • SPDR® S&P Biotech ETF

                  •  

                    1,683,857

                  • 3.59

                  • 1.25

                  • T. Rowe Price Health Sciences Fund

                  •  

                    1,513,269

                  • -0.33

                  • 1.11

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Federated Global Inv Mgmt Corp

                  •  

                    13,584,600

                  • +5,961.85%

                  • 9.99

                  • PRIMECAP Management Company

                  •  

                    11,129,830

                  • -5.74%

                  • 8.18

                  • Fidelity Management and Research Company

                  •  

                    11,044,370

                  • -9.93%

                  • 8.12

                  • RA Capital Management, LLC

                  •  

                    9,982,578

                  • +34.24%

                  • 7.34

                  • Baker Bros Advisors LLC

                  •  

                    5,681,237

                  • +124.40%

                  • 4.18

                  • BlackRock Fund Advisors

                  •  

                    4,605,886

                  • -12.03%

                  • 3.39

                  • Vanguard Group, Inc.

                  •  

                    4,186,154

                  • +2.21%

                  • 3.08

                  • State Street Corp

                  •  

                    3,868,146

                  • -4.77%

                  • 2.84

                  • Janus Capital Management LLC

                  •  

                    3,783,506

                  • +77.41%

                  • 2.78

                  • Deerfield Management Co

                  •  

                    3,717,013

                  • -1.83%

                  • 2.73

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Slow Growth

                  Style

                  Small Growth

                  Dyax Corp was incorporated in the state of Delaware in the year 1989, and merged with Protein Engineering Corporation in 1995. It is a biopharmaceutical company focused on Hereditary Angioedema and Other Plasma-Kallikrein-Mediated Di...moresorders and Licensing and Funded Research Portfolio. The Company develops and commercializes treatments for hereditary angioedema and to identify other disorders that are mediated by plasma kallikrein. It is engaged in identifying and developing treatments for patients who experience PKM angioedema. Plasma kallikrein, an enzyme found in blood, produces bradykinin, a protein that causes blood vessels to enlarge or dilate, which can cause swelling known as angioedema. Excess plasma kallikrein activity plays a role in HAE and could potentially play a role in a number of in...moreflammatory diseases, including Crohn’s disease, psoriasis, rheumatoid arthritis, and various mast cell disorders. It also develops KALBITOR for the treatment of acute attacks of HAE. KALBITOR is currently distributed through a limited network of wholesale, hospital and specialty pharmacy arrangements. Its portfolio of product candidates being developed by licensees using its phage display technology. For KALBITOR as a treatment for HAE, its competitors include: Manufacturers of corticosteroids. Other competitors for the treatment of HAE are companies that are developing small molecule plasma kallikrein inhibitors. The preclinical study and clinical testing, manufacture, labeling, storage, record keeping, advertising, promotion, export, and marketing, among other things, of its products and product candidates, including KALBITOR and those of its licensees, are subject to extensive regulation by governmental authorities in the United States and other countries.lessless

                  Key People

                  Gustav A. Christensen

                  CEO/Director/President

                  Henry E. Blair

                  Chairman of the Board/Director

                  George V. Migausky

                  CFO/Chief Accounting Officer/Executive VP

                  Burt A. Adelman,M.D.

                  Chief Medical Officer/Executive VP

                  Andrew D. Ashe

                  Executive VP/General Counsel

                  • Dyax Corp

                  • 55 Network Drive

                  • Burlington, MA 01803

                  • USA.Map

                  • Phone: +1 617 225-2500

                  • Fax: +1 617 225-2501

                  • dyax.com

                  Incorporated

                  1989

                  Employees

                  120

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: